JOHN R - Center for Adaptive Neural Systems - Arizona State ...

Denise I. Campagnolo, M.D. 

Faculty, Barrow Neuroimmunology Program 

Director, Clinical Research, Neuroimmunology Program 

St. Joseph’s Hospital and Medical Center 

Barrow Neurology Clinics 

500 West Thomas Road, Suite 710 

Phoenix, Arizona 85013 

602-406-3887 Telephone 

602-798-0697 Facsimile 

denise.campagnolo@chw.edu E-mail 

EDUCATION 

1980 – 1981 Randolph-Macon College 

Ashland, Virginia 

Degree: None 

1981 – 1981 Ohio Dominican College 

Columbus, Ohio 

Degree: None 

1982 – 1984 Ohio State University 


Degree: B.S. 

1992 – 1993 University of Medicine and Dentistry of New Jersey 

Newark, New Jersey 

Degree: M.S., Neuroscience 

MEDICAL SCHOOL 

1984 – 1988 Ohio State University College of Medicine 


Degree: M. D. 

INTERNSHIP 

1988 General Surgery Training 

St. Barnabas Medical Center 

Livingston, New Jersey 

1988 – 1989 Rotating Transitional Internship 

Riverside Methodist Hospital 

Columbus, Ohio

Denise Campagnolo, M.D. - Curriculum Vitae 

Page 2 of 22 

RESIDENCY 

1989 – 1991 Resident 

Department of Physical Medicine and Rehabilitation 

UMDNJ-New Jersey Medical School 


1991 – 1992 Chief Resident 




FELLOWSHIP 

1992 – 1993 Research Fellowship 




CURRENT LICENSURE 

State of Arizona 

License Number: 32640 

BOARD CERTIFICATIONS 

1998, 2007 American Board of Physical Medicine and Rehabilitation 

Subspecialty: Spinal Cord Injury Medicine 

1994, 2004 American Board of Electrodiagnostic Medicine, Diplomate 

1993, 2003 American Board of Physical Medicine and Rehabilitation 

CURRENT POSITIONS 

2004 – Present Investigator 



Phoenix, Arizona 

2004 – Present Director of Multiple Sclerosis Clinical Research 

Staff Physiatrist 




Revised 6/9/2008


Page 3 of 22 

2005 – 2008 Director, NARCOMS Project for Consortium of MS Centers 


2004 – Present Clinical Faculty/Adjunct 

Center for Adaptive Neural Systems 

Arizona State University 

Tempe, Arizona 

PREVIOUS POSITIONS AND APPOINTMENTS 

2000 – 2004 Associate Professor, Physical Medicine and Rehabilitation 



University Hospital, B-261 


1998 – 2004 Consulting Privileges 

Overlook Hospital 

Summit, New Jersey 

1993 – 2004 Staff Physiatrist, Clinical Director of SCI Program 


University Hospital 


1996 – 2001 Consulting Privileges 

Bayonne Hospital 

Bayonne, New Jersey 

1995 – 2000 Assistant Professor, Physical Medicine and Rehabilitation 





1993 – 1995 Instructor 





1991 – 1992 Clinical Instructor II 





Revised 6/9/2008


Page 4 of 22 

HONORS 

2000 Outstanding Women in Somerset County 

Medicine/Health Services 

1999 Alumni Award 

UMDNJ-Department of Physical Medicine and Rehabilitation 

1999 Humanism in Medicine Award 

Healthcare Foundation of New Jersey 

1995 Annual Teaching Award 

UMDNJ-NJMS Department of Physical Medicine and Rehabilitation 

1994 Excellence in Research Writing Award 

American Journal of Physical Medicine and Rehabilitation 

1993 Education and Research Foundation – Young Investigator’s Award 

American Academy of Physical Medicine and Rehabilitation 

1988 Alpha Omega Alpha Honor Medical Society 

1987 Third Place for Platform Presentation 

Landacre Society Research Forum 

Ohio State University College of Medicine 

CURRENT PROFESSIONAL MEMBERSHIPS 

Alpha Omega Alpha Honor Medical Society 

Arizona Medical Association 

American Association of Neuromuscular & Electrodiagnostic Medicine 

(AANEM) 

Association of Academic Physiatrists 

American Paraplegia Society 

Revised 6/9/2008


Page 5 of 22 

COMMITTEE MEMBERSHIPS 

2008 – Present University of Arizona College of Medicine, Phoenix, Medical Student 

Clerkship Directors Committee 

2006 - Present SJHMC Institutional Review Board 

2004 – Present BNI Neurology Graduate Medical Education Committee 

2002 – Present American Paraplegia Society Research Committee 

2001 – Present American Board of Physical Medicine and Rehabilitation Spinal Cord Injury 

Medicine Board Question Item Writing Committee 

2003 – 2004 OSCE Committee; University Hospital, Department of Physical Medicine and 

Rehabilitation 

2002 – 2004 PRIME 2005 Education Committee; UMDNJ-New Jersey Medical School 

2000 – 2004 Chair, Graduate Medical Education Committee; University Hospital, 


2000 – 2004 AAEM – Research Pilot Study Review Task Force 

1999 – 2004 Women’s Talk Force Committee of the Association of Academic Physiatrists 

1997 – 2004 Undergraduate Medical Education Committee; University Hospital, 


1996 – 2004 Clinical Practice Committee; University Hospital 

1996 – 2004 Spinal Cord Medicine Fellowship Committee; University Hospital, Department 

of Physical Medicine and Rehabilitation 

1995 – 2004 Medical Fellowship Committee; University Hospital, Department of Physical 

Medicine and Rehabilitation 

1993 – 2004 Neurosurgical Advisory Group; University Hospital 

1993 – 2004 Chair of the Spinal Cord Injury Program Committee; University Hospital 

1992 – 2004 Match Committee; NJMS, Department of Physical Medicine and 

Rehabilitation 

2000 – 2003 Graduate Medical Education Committee; UMDNJ-New Jersey Medical School 

2001 – 2002 House staff Disciplinary and Impairment Ad Hoc Committee; UMDNJ – New 

Revised 6/9/2008


Page 6 of 22 

Jersey Medical School 

1999 – 2001 Institutional Review Board; UMDNJ-New Jersey Medical School 

1998 – 1999 Research Committee; University Hospital, Department of Physical Medicine 

and Rehabilitation 

1994 – 1999 Undergraduate Education Committee of the Association of Academic 

Physiatrists 

1994 – 1998 Academic Programs and Policies Committee; UMDNJ-New Jersey Medical 

School 

1993 – 1997 Clinical Curriculum Subcommittee; UMDNJ-New Jersey Medical School 

1992 – 1997 Chair, Undergraduate Medical Education Committee; University Hospital, 


1991 – 1994 Graduate Medical Education Committee; University Hospital, Department of 

Physical Medicine and Rehabilitation 

1991 – 1992 Medical Society of New Jersey Council of Public Health, Resident 

Representative 

1991 – 1992 American Academy of Physical Medicine and Rehabilitation, Resident 

Physician Council, Research Committee, Northeast Representative 

EDITORIAL BOARDS 

2007 – Present Associate Editor, American Journal of Physical Medicine and Rehabilitation 

2001 – Present Chief Editor, eMedicine – online textbook 

1999 – Present Reviewer, Journal of spinal Cord Injury Medicine 

1995 – Present Reviewer, Archives of Physical Medicine and Rehabilitation 

1994 – Present Reviewer, American Journal of Physical Medicine and Rehabilitation 

GRANTS 

1. Spinal Cord Injury Education Grant, June 1995 

The Upjohn Company Grant Program # 00433 

Principal Investigator 

2. Immune Function in Spinal Cord Injury. Henry H. Kessler Foundation Grant, September 

1995 


Revised 6/9/2008


Page 7 of 22 

3. Academic Information Technology Advisory Committee. Instructional Technology Grant 

1996 


4. Immune System Dysfunction Following Spinal Cord Injury. Dean’s Biomedical Research 

Grant, 1997 


5. Factors That Contribute to Infections During SCI Rehabilitation. PVA – Spinal Cord 

Research Foundation, 2001 – 2004 


6. Sympathetic Nervous System (SNS) Dysregulation and Diminished Cellular Immunity in 

Spinal Cord Injury. Christopher Reeve Paralysis Foundation, 2001 – 2003 

Co-Principal Investigator 

7. Immunity and Health Following Spinal Cord Injury. NIH – K24 – Career Award, Start date 

July 1, 2004 Principal Investigator 

8. NK Cells as Surrogate Disease Marker in MS. Barrow Neurological Foundation 2007-2008 

awarded $ 69,696.00 


CURRENT RESEARCH: 

1. Immunity and Spinal Cord Injury Study 


2. A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study, to Compare 

the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of 

Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection 

in Subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS) 


3. NARCOMS Patient Registry 

Co-Investigator 

4. H-reflex to monitor motor pathway function in patients undergoing spine surgery 


5. A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood 

Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating 

Diseases 

Revised 6/9/2008


Page 8 of 22 


6. Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral xxxxx- 

SR in Subjects with Multiple Sclerosis 



SR in Subjects with Multiple Sclerosis Who Participated in the xxxxx Trial 


8. Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of 

Oral xxxxx-SR (10 mg b.i.d.) in Patients with Multiple Sclerosis 



SR in Patients with Multiple Sclerosis (MS) who Participated in the xxxxx Trial 


10. Development of Peripheral Blood and Urine Diagnostics and Biomarkers for Alzheimer's 

Disease ("Alzheimer's Diagnostic Study") 


11. An Immunological Study of Atorvastatin (Lipitor®) as Combination Therapy with 

Glatiramer Acetate (Copaxone®) versus Glatiramer Acetate Alone in Patients with Active 

Relapsing-Remitting Multiple Sclerosis (RRMS) 


12. Specimen and Data Collection and Archiving for Immunological Investigations Aiming to 

Understand the Immunological Mechanism of Multiple Sclerosis (MS) and Identify New 

Targets For Immune Therapies for Multiple Sclerosis and Other Autoimmune Diseases and 

Neuroinflammatory Disorders 


13. Gene Expression Assay of Patients with Multiple Sclerosis and Other Neurological Diseases, 

On and Off Immunological Therapy, Compared to Healthy Controls 


14. International, randomized, multicenter, phase IIIb study in patients with relapsing-remitting 

multiple sclerosis comparing over a treatment period of 104 weeks: Double-blinded safety, 

tolerability, and efficacy of Betaseron®/Betaferon® xxxxx micrograms (xxxxx MIU) and 

Betaseron®/Betaferon® xxxxx micrograms (xxxxx MIU), both given subcutaneously every 

other day; and Rater-blinded safety, tolerability, and efficacy of Betaseron®/Betaferon® 

subcutaneously every other day with Copaxone® 20 mg subcutaneously once daily 


Revised 6/9/2008


Page 9 of 22 

15. International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of 

patients with relapsing multiple sclerosis with: (Phase A) double-blind Betaseron/Betaferon 

xxxxx µg or xxxxx µg or open-label Betaseron/Betaferon xxxxx µg and (Phase B) open-label 

Betaseron/Betaferon xxxxx µg 


16. Long-Term Follow-Up Health Survey of Subjects Previously Treated with xxxxx 


17. Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker 

Response 


18. A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) 

Comparison Study to Evaluate the Efficacy and Safety of xxxxx in Subjects With Relapsing- 

Remitting Multiple Sclerosis 


19. A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety 

of xxxxx in Subjects with Secondary Progressive Multiple Sclerosis 


20. A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter 

Study to Evaluate the Safety and Efficacy of xxxxx (MabThera®/Rituxan®) in Adults with 

Primary Progressive Multiple Sclerosis 


21. A Phase II, Proof-of-Concept, Randomized, Double-Blind, Parallel-Group, Placebo- 

Controlled, Multicenter Study to Evaluate the Safety and Efficacy of xxxxx 

(MabThera®/Rituxan®) in Adults with Relapsing-Remitting Multiple Sclerosis 


22. A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous 

Alemtuzumab to 3-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment- 

Naïve Patients with Relapsing-Remitting Multiple Sclerosis 


23. A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of 

Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous 

Interferon Beta 1a (Rebif®) in Patients with Relapsing Remitting Multiple Sclerosis Who 

Have Relapsed On Therapy 


Revised 6/9/2008


Page 10 of 22 

24. A Blood Test for Multiple Sclerosis: Detection and Analysis of a Circulating Multiple 

Sclerosis Associated Antigen 


25. A Randomized, Double-Blinded, Placebo-Controlled, Multi-center Study to Evaluate the 

Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High 

Risk of Conversion to Multiple Sclerosis 


26. A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of 

Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing 

Remitting Multiple Sclerosis 


27. Biomarkers in Multiple Sclerosis 


28. A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study 

comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered 

orally once daily versus interferon β-1a (Avonex®) administered i.m. once weekly in 

patients with relapsing-remitting multiple sclerosis with optional Extension Phase 


29. A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study 

comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered 

orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis 


30. A Phase 2 Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of 

Subcutaneous Daclizumab® in Patients with Active, Relapsing Forms of Multiple Sclerosis 


31. A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, 

Tolerability and Efficacy Study on Add-on Cladribine Tablet Therapy with Rebif® New 

Formulation in Multiple Sclerosis Subjects with Active Disease 


32. Online Validation of Multiple Sclerosis International Quality of Life (MuSI-QoL) 

Questionnaire 


33. A Multi-Centered, Two Arm, Open Label Extension Study (to protocol xxxxx) to Evaluate 

the Long-Term Safety and Efficacy of Short-Term Induction Treatment with Mitoxantrone 

(Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) vs. Chronic 

Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis 


Revised 6/9/2008


Page 11 of 22 

34. Immunological Studies for a Multi-Centered, Randomized, Two-Arm, Open Label Study to 

Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone 

(Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic 

Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis 


35. Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with 

relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of 

two doses of xxxxx over 24 weeks with a rater-blind MRI follow-up over 12 weeks 


COMPLETED RESEARCH: 

1. The Impact of CarePartner Stress in Multiple Sclerosis 

Co-Principal Investigator 

2. A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, 

Safety, Tolerability, and Efficacy Study of the xxxxx in Subjects With Multiple Sclerosis 

With a 24-Week Double-Blind, Active Extension Phase 


3. Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and 

Efficacy of Oral xxxxx-SR (xxxxx mg B.I.D.) in Subjects with Multiple Sclerosis 


4. A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of 

xxxxx (xxxxx/xxxxx) in the Treatment of Pseudobulbar Affect in Patients with Multiple 

Sclerosis Co-Investigator 

5. An Open-Label Multicenter Study to Assess the Safety of xxxxx (xxxxx/xxxxx) in the 

Treatment of Patients with Pseudobulbar Affect 


6. Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different 

Dose Regimens of IGIV-Chromatography (IGIV-C), 10% Treatment on Relapses in Patients 

with Relapsing Remitting Multiple Sclerosis 


7. Phase I Trial of Immunotherapy with xxxxx Alone or Combined with Atorvastatin in Patients 

with Multiple Sclerosis 


8. An Exploratory Study of Blood Markers of Disease Activity in Multiple Sclerosis 


Revised 6/9/2008


Page 12 of 22 

9. xxxxx Immunotherapy in Relapsing Remitting Multiple Sclerosis 


10. A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy 

and Safety of Betaseron® xxxx ug Subcutaneously Every Other Day with Avonex® xxxxx 

ug Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients 

Previously Treated with Avonex® 


11. A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX® Compared with 

AVONEX® in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or 

Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough 

Disease on AVONEX® Monotherapy 


12. A Randomized, Double-blind, Placebo-controlled, Parallel group, Dose-ranging Study to 

Investigate the MRI Efficacy and the Safety of Three Months Administration of xxxxx 

(xxxxx-xxxxx mg twice daily) in Subjects with Relapsing Multiple Sclerosis 


13. Quality of Life/COST Study 


14. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability 

and Efficacy of xxxxx in Patients with Relapsing Multiple Sclerosis 


15. Phase IV, multicenter, open label, randomized study of Rebif xxxxx mcg administered three 

times per week by subcutaneous injection compared with Copaxone® xxxxx mg 

administered daily by subcutaneous injection in the treatment of relapsing remitting multiple 

sclerosis 


16. MuSI-QoL Project: Field Study Design 


17. A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, 

Tolerability and Safety of Copaxone® to that of High Dose Interferon (Betaseron® or 

Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients 


Revised 6/9/2008


Page 13 of 22 

18. A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, 

Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) 

Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with 

Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis 


19. A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the 

Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated 

with Glatiramer Acetate (GA) 


BOOKS 

Spinal Cord Medicine. Eds: Kirshblum S, Campagnolo DI, DeLisa J. Lippincott Williams and 

Wilkins: publication date January 2002. 

PUBLICATIONS 

1. Campagnolo DI, Gower WR, Fabri J, Sparks J, Mekhjian HS, O’Dorisio TM, Ellison EC. 

Effect of Somatostatin Analogue (SMS 201-995) on Molecular Species of Gastrin in 

Gastrinoma. Surgery 102:982-987, 1987 Dec. 

2. Bach J, Campagnolo DI, Hoeman S. Life Satisfaction of Individuals with Duchenne 

Muscular Dystrophy Using Long-Term Mechanical Ventilatory Support. American Journal 

of Physical Medicine and Rehabilitation 70(3):129-135, 1991 Jun. 

3. DeLisa JA, Jain SS, Campagnolo DI, McCutcheon P. Selecting a Physical Medicine and 

Rehabilitation Residency. American Journal of Physical Medicine and Rehabilitation 

71(2):72-76, 1992 Apr. 

4. Bach J, Campagnolo DI. Psychosocial Adjustment of Post Poliomyelitis Ventilator Assisted 

Individuals. Archives of Physical Medicine and Rehabilitation 73(10):934-939, 1992 Oct. 

5. DeLisa JA, Jain SS, Campagnolo DI, McCutcheon P. A Method to Assess Trainee Profiles 

of Medical Students Attracted to Our Physical Medicine and Rehabilitation Residency 

Training Program. American Journal of Physical Medicine and Rehabilitation 72(1):2-5, 

1993 Feb. 

6. Jain SS, DeLisa JA, Campagnolo DI. Chief Residents in Physiatry: Expectations Versus 

Training. American Journal of Physical Medicine and Rehabilitation 72:262-265, 1993 Oct. 

7. Campagnolo DI, Linsenmeyer TA, Jacalan C, Pak N, Averill A. Prevalence of urinary 

incontinence after brain injury. Neuro Rehabilitation. 1994;4(4):255-258. 

Revised 6/9/2008


Page 14 of 22 

8. Malanga G, Campagnolo DI. Clarification of the ‘Pronator Reflex.’ American Journal of 

Physical Medicine and Rehabilitation. 1994;73(5):338-340. 

9. Kirshblum S, Campagnolo DI. Heterotopic Ossification after Total Hip Replacement. 

Journal of Back and Musculoskeletal Medicine. 1994;4(3):207-217. 

10. Katz RT, Campagnolo DI. Pharmacologic Management of Spasticity. PM&R State of the 

Art Review. 1994;8(3):473-480. 

11. DeLisa JA, Jain SS, Campagnolo DI. Factors Used by Physical Medicine and 

Rehabilitation Residency Training Directors to Select Their Residents. American Journal of 

Physical Medicine and Rehabilitation 73(3):152-156, 1994 Jun. 

12. Jain SS, DeLisa JA, Campagnolo DI. Methods of Evaluation of Physical Medicine and 

Rehabilitation Residents’ Clinical Competency. American Journal of Physical Medicine and 

Rehabilitation 73(4):234-239, 1994 Jul-Aug. 

13. Campagnolo DI, Keller SE, DeLisa JA, Sipski ML, Glick T, Schleifer SJ. Alteration of 

Immune System Function in Tetraplegics: A Pilot Study. American Journal of Physical 

Medicine and Rehabilitation 73(6):387-393. 1994 Nov-Dec. 

14. Katz RT, Campagnolo DI, Goldberg G, Parker JC, Pine ZM, Whyte J. Critical Evaluation of 

Clinical Research. Archives of Physical Medicine and Rehabilitation 76(1):82-93, 1995 Jan. 

15. DeLisa JA, Jain SS, Campagnolo DI, Kirshblum SC, Findley T. Factors Influencing the 

Specialty Choice of the Physical Medicine and Rehabilitation Graduating Class of 1994 and 

the Entering Class of 1995. American Journal of Physical Medicine and Rehabilitation 

74(4):262-270, 1995 Jul-Aug. 

16. Linsenmeyer TA, Campagnolo DI, Chou I. Silent Autonomic Dysreflexia During Voiding 

in Men with Spinal Cord Injuries. Journal of Urology 155(2):519-522, 1996 Feb. 

17. Campagnolo DI, Davis BA, Blacksin MF. Computed Tomography – Guided Aspiration of a 

Ganglion Cyst of the Anterior Cruciate Ligament: A Case Report. Archives of Physical 

Medicine & Rehabilitation 77(7):732-3, 1996 Jul. 

18. Campagnolo DI, DeLisa JA. Drugs used to improve recovery following spinal cord injury. 

Medula Espina. 1996;July:137-142. 

19. DeLisa JA, Kirshblum SC, Jain SS, Campagnolo DI, Johnston M, Wood KD, Findley T. 

Practice and Career Satisfaction Among Physiatrists. A National Survey. American Journal 

of Physical Medicine and Rehabilitation 76(2):90-101, 1997 Mar-Apr. 

20. Campagnolo DI, Esquieres RE, Kopacz KJ. Effect of Timing of Stabilization on Length of 

Stay and Medical Complications Following Spinal Cord Injury. Journal of Spinal Cord 

Medicine 20(3):331-334, 1997 Jul. 

Revised 6/9/2008


Page 15 of 22 

21. Campagnolo DI, Bartlett JA, Keller SE, Sanchez W, Oza R. Impaired Phagocytosis of 

Staphylococcus Aureus in Complete Tetraplegics. American Journal of PM&R 6(4):276-280, 

1997 Jul-Aug. 

22. Campagnolo DI, Melchiorre PI. Bilateral patellar tendon rupture after minor trauma. 

European Journal of Physical Medicine and Rehabilitation. 1998;8(3):74-76. 

23. Campagnolo DI, DeLisa JA. Medical complications of spinal cord injury. J Clinical 

Rehabilitation. 1998;7(4):402-414. 

24. Kirshblum SC, DeLisa JA, Campagnolo DI. Mandatory Clerkship inPhysical Medicine and 

Rehabilitation: Effect on Medical Students’ Knowledge of Physiatry. Archives of Physical 

Medicine & Rehabilitation 79(1):10-3, 1998 Jan. 

25. Nadler S, Campagnolo DI, Tomaiao A, Stitik T. High Lumbosacral Disc: A Diagnostic and 

Treatment Dilemma. American Journal of PM&R 77(6):538-544, 1998 Nov-Dec. 

26. Campagnolo DI, Bartlett JA, Chatterton R, Keller SE. Adrenal and Pituitary Hormone 

Patterns Following Spinal Cord Injury. American Journal of PM&R 78(4):361-366, 1999 

Jul-Aug. 

27. Campagnolo DI, Bartlett JA, Keller SE. Influence of Neurologic Level of Injury on Immune 

Function Following SCI: A Review. Journal of Spinal Cord Medicine 23(2):121-128, 2000. 

28. Campagnolo DI, Romello MA, Park YI, Foye PM, DeLisa JA. A Technique for Studying 

Conduction in the Lateral Cutaneous Nerve of the Calf. Muscle and Nerve 23(8):1277-1279, 

2000 Aug. 

29. Qian T, Campagnolo DI, Kirshblum S. High-Dose Methylprednisolone May Do More 

Harm for Spinal Cord Injury. Medical Hypotheses 55(5):452-453, 2000 Nov. 

30. Kirshblum SC, Memmo P, Kim N, Campagnolo DI, Millis S. Comparison of the Revised 

2000 ASIA Classification Standards with the 1996 Guidelines. American Journal of PM&R 

81(7):502-505, 2002 Jul. 

31. Campagnolo DI, Filart RA, Millis SR, Lann DE. The Appropriateness of the Ilfeld 

Psychiatric Symptom Index as a Screening Tool for Depressive Symptomatology in Persons 

with Spinal Cord Injury. Journal of Spinal Cord Medicine 25(2):129-132, 2002. 

32. Campagnolo DI. Stier KT. Sanchez W. Foye PM. DeLisa JA. Spinal Cord Injury Computer- 

Assisted Instruction for Medical Students. American Journal of Physical Medicine & 

Rehabilitation 82(4):316-9, 2003 Apr. 

33. Tomassoni P, Campagnolo DI. Autonomic Dysreflexia: One More Way EMS Can 

Positively Affect Patient Survival. Journal of Emergency Medical Services 28(12):46-51 

2003 Dec. 

Revised 6/9/2008


Page 16 of 22 

34. Kim SR, Stitik TP, Foye PM, Greenwald BD, Campagnolo DI. Critical review of 

prolotherapy for osteoarthritis, low back pain, and other musculoskeletal conditions: a 

physiatric perspective. Am J Phys Med Rehabil. 83(5):379-89, 2004 May. 

35. Millis SR. Campagnolo DI. Kirshblum S. Elovic E. Jain SS. DeLisa JA. Improving resident 

research in physical medicine and rehabilitation: impact of a structured training program. J. 

of Spinal Cord Med 27(5):428-33, 2004. 

36. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo DI, Vollmer T. Validation of 

the NARCOMS registry: fatigue assessment. Multiple Sclerosis 11(5):583-4, 2005 Oct. 

37. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo DI, Vollmer T. Changes in 

ascertainment of multiple sclerosis. Neurology 65(7):1066-1070, 2005 Oct 11. 

38. Liu R, La Cava A, Bai X, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van 

Kaer L, Shi F. Cooperation of iNKT cells and CD4+CD25+ T Regulatory Cells in the 

Prevention of Autoimmune Myasthenia. J Immunol. 175(12):7898-904, 2005 Dec 15. 

39. Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, Vollmer TL. Do Th2 cells mediate the 

effects of glatiramer acetate in experimental autoimmune encephalomyelitis Int Immunol. 

18(4):537-44, April 2006. 

40. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo DI. Does multiple sclerosis– 

associated disability differ between races Neurology 66(8):1235-40, 2006 Apr 25. 

41. Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer 

TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J 

Immunol. 176(9):5247-54, May 1, 2006. 

42. Campagnolo D. North American Research Committee on Multiple Sclerosis. International 

Journal of MS Care. 2006;8(3)110-111. 

43. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the Management of 

Multiple Sclerosis-Related Bladder Symptoms. Neurology 68(23):1971-8, 2007 Jun 5. 

44. Marrie RA, Cutter G, Tyry T, Campagnolo, DI, Vollmer, T. Validation of the NARCOMS 

Registry: Diagnosis. Multiple Sclerosis 13(6):770-5, 2007 Jul. 

45. Bar-Or A, Vollmer* T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili 

F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz 

PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in 

multiple sclerosis after immunization with DNA encoding myelin basic protein in a 

randomized, placebo-controlled phase I/II trial. Arch Neurol 64(10):1385-6, 2007 Oct. 

Revised 6/9/2008


Page 17 of 22 

46. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, Campagnolo DI, Shi FD, Vollmer 

TL. CD4(+)CD25(+) Regulatory T-cells Contribute to the Therapeutic Effects of Glatiramer 

Acetate in Experimental Autoimmune Encephalomyelitis. Clinical Immunology, 125(1):34- 

42, 2007 Oct. 

47. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Arnold 

D. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple 

sclerosis. In press Multiple Sclerosis 

48. Marrie, R.A., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D, & Vollmer, T. 

Comorbidity, socioeconomic status and multiple sclerosis. Multiple Sclerosis 2008 (in 

press). 

49. Piao WH, Wong R, Bai XF, Huang J, Campagnolo D, Dorr RT, Vollmer T, Shi F. 

Therapeutic effect of anthracene-based anti-cancer agent ethonafide in an animal model of 

multiple sclerosis. Journal of Immunology 179(11):7415-23, 2007 Dec 1. 

50. Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, 

Vollmer TL, Bai XF, La Cava A, Shi FD. IL-21 Modulates CD4+ CD25+ Regulatory T-cell 

Homeostasis in Experimental Autoimmune Encephalomyelitis. Scandinavian Journal of 

Immunology 67(1):37-46, 2008 Jan. 

51. Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, Shi FD. 

Therapeutic Effect of Anthracene-Based Anticancer Agent Ethonafide in an Animal Model 

of Multiple Sclerosis. J Immunol 179:7415-23, 2007 Dec. 

52. Campagnolo DI, Dixon D, Schwartz J, Bartlett JA, Keller SE. Altered Innate Immunity 

Following Spinal Cord Injury. Spinal Cord Volume 46 Issue 7, 2008. 

53. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Patients with Multiple Sclerosis 

Reliably Report Smoking Status Submitted American Journal of Epidemiology 

CHAPTERS 

1. Katz RT, Campagnolo DI, Goldberg G, Parker JC, Pine ZM, Whyte J. Research in physical 

medicine and rehabilitation. In: Braddom RL, ed. Textbook of Physical Medicine and 

Rehabilitation. Philadelphia, Pa: W.B. Saunders Publishers; 1996:255-272. 

2. Campagnolo DI, Horton JA. Rehabilitation prescription for the paraplegic. In: Shankar K, ed. 

Exercise Prescription. Philadelphia, Pa: Hanley and Belfus Inc; 1998:247-264. 

3. Shi FD, Campagnolo DI, Vollmer TL. Immune therapy for multiple sclerosis: altered peptide 

ligands and statins. In: Cook S. Handbook of Multiple Sclerosis, 4th ed. 

Revised 6/9/2008


Page 18 of 22 

ABSTRACTS 

1. Campagnolo DI, Bitwinski J, Bach J. Assessment of life satisfaction for ventilator supported 

polio patients. Archives of Physical Medicine and Rehabilitation. 1991;72(10):801-802. 

2. DeLisa JA, Jain SS, Campagnolo DI. Analysis of factors important in selecting a physical 

medicine and rehabilitation residency. American Journal of Physical Medicine and 

Rehabilitation. 1992;71(4):251. 

3. Campagnolo DI, Katz RT. Successful treatment of akinetic mutism with a post-synaptic 

dopamine agonist. (Abstract) Archives of Physical Medicine and Rehabilitation. 

1992;73(10):975. 

4. Malanga G, Campagnolo DI. Clarification of the ‘Pronator Reflex.’ Archives of Physical 

Medicine and Rehabilitation. 1992;73(10):969. 

5. Jain SS, DeLisa JA, Campagnolo DI. Chief residents in physiatry: expectations versus 

training. American Journal of Physical Medicine and Rehabilitation. 1993;72(44):234. 

6. Campagnolo DI, Linsenmeyer TA, Jacalan C, Pak N, Averill A. Assessment of voiding 

dysfunction following brain injury. Archives of Physical Medicine and Rehabilitation. 

1993;74(11):1245. 

7. Kirshblum S, Campagnolo DI, DeLisa JA. The effect of mandatory clerkship on medical 

students’ perception of physiatry. Archives of Physical Medicine and Rehabilitation. 

1993;74(11):1236. 

8. Kirshblum S, Campagnolo DI, DeLisa JA. Opinions of fourth-year medical student applying 

to PM&R residency programs. Archives of Physical Medicine and Rehabilitation. 

1993;74(11)1236. 

9. Jain SS, DeLisa JA, Campagnolo DI. Methods of evaluation of physical medicine and 

rehabilitation residents’ clinical competency. American Journal of Physical Medicine and 


10. DeLisa JA, Jain SS, Campagnolo DI. Factors used by physical medicine and rehabilitation 

residency training directors to select their residents. American Journal of Physical Medicine 

and Rehabilitation. 1994;73(2):141. 

11. Campagnolo DI, Keller SE, Sipski ML. Lymphocyte dysfunction following spinal cord 

injury. Journal of the American Paraplegia Society. 1994;17(2):116. 

12. Campagnolo DI, Keller SE, Sipski ML. Lymphocyte dysfunction in tetraplegics. Journal of 

the American Paraplegia Society. 1994;17(4):197. 

13. Campagnolo DI, Keller SE, Sipski ML. Immune system dysfunction following spinal cord 

injury. American Journal of Physical Medicine and Rehabilitation. 1994;73(2):141. 

Revised 6/9/2008


Page 19 of 22 

14. Ferraro DJ, Sipski ML, Campagnolo DI. The rehabilitation of a deaf and mute tetraplegic. 

Journal of the American Paraplegia Society. 1994;17(4):222. 

15. Campagnolo DI, Keller SE, Grimaldi L. Natural killer cell function in tetraplegic patients. 

Archives of PM&R. 1995;76(11):1032. 

16. Campagnolo DI, DeLisa JA, Foye PM. Lateral cutaneous nerve of the calf: a nerve 

conduction technique. American Association of Electrodiagnostic Medicine (AAEM) 

abstract. Muscle and Nerve. October 2000;23(10):1630-1631. 

17. Qian T, Campagnolo DI, Kirshblum S. High-dose methylprednisolone may do more harm 

for spinal cord injury. Compendium of Abstracts in Spinal Cord Medicine. June 

2001;6(1):25. 

18. Qian T, Campagnolo DI, Kirshblum S, DeLisa J. High-dose methylprednisolone may cause 

myopathy in patients with acute spinal cord injury. American Journal of Physical Medicine 

and Rehabilitation. 2001;80(4):316. 

19. Chen B, Foye PM, Campagnolo DI, Stitik TP, Nadler SF, DeLisa JA. Carpal tunnel 

syndrome after motor vehicle crash. Archives of PM&R. September 2001;82(9):1314. 

20. Foye PM, Stitik TP, DePrince ML, Nadler SF, Campagnolo DI, Chen B, DeLisa JA. 

Medical students’ responses to real versus simulated patients within a musculoskeletal 

physical exam workshop. Archives of PM&R. September 2001;82(9):1333. 

21. Campagnolo DI, Keller SE, Brandman D, Yeger M. Impaired Cellular Immunity after 

Spinal Cord Injury. Am J Phys Med Rehabil. 2003;82(3):237. 

22. Campagnolo DI, Bromberg R, Brandman D, DeLisa JA. Enhancing resident physician 

training with personal digital assistants. Am J Phys Med Rehabil. 2003;82(3):238 

23. Liu R, Pollard MK, LaCava A, Price M, Rhodes S, Campagnolo DI, et al. Treatment of a B 

cell mediated autoimmune disease, myasthenia gravis in mice by activation of natural killer 

TT cells. Neurology. 2005;64(6) Supplement 1:A78. 

24. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo DI. NARCOMS validation study. 

Neurology. 66, Supplement 2, P04.109. 

25. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo DI. Does Multiple Sclerosis– 

associated disability differ between Races Neurology. 66, Supplement 2. P04.118. 

26. Zvonkina VY, Campagnolo DI, Frey JL. Effects of sleep deprivation during the 80-hour 

work week. Sleep. 2006;29, Supplement S, A119. 

Revised 6/9/2008


Page 20 of 22 

27. Bar-Or A, Antel J, Bodner CA, Campagnolo DI, Gianettoni J, Jalili F, Kachuck N, Lapierre 

Y, Niino M, Oger J, Price M, Rhodes S, Shi F, Steinman L, Valone F, Vollmer T, Weiner L, 

Garren H. Antigen-specific immunomodulation in multiple sclerosis patients treated with 

MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Submitted 

AAN 2006. 

28. Jee Y, Liu R, Price M, Campagnolo DI, Shi FD, Vollmer TL. CD4+CD25+ regulatory T 

cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune 

encephalomyelitis. 58th American Academy of Neurology Annual Meeting, April 1-8, 2006, 

San Diego Convention Center in San Diego, CA. (Poster #181. Poster Session P05. April 6, 

7:30 a.m.-12:00 p.m.) 

29. Campagnolo D, Shi F, Rhodes S, Liu R, Piao W, Kala M, Sood R, Vollmer T. Natural 

Killer Cell Cytotoxicity in Treatment Naïve Multiple Sclerosis Subjects. Consortium of 

Multiple Sclerosis Centers 2007 Annual Meeting, Washington D.C.. Poster S14 

REVIEWS 

1. Katz RT, Campagnolo DI. Pharmacologic management of spasticity. Physical Medicine and 

Rehabilitation State of the Art Reviews. 1994;8(3):473-480. 

2. Campagnolo DI. Book Review: Handbook of Neurorehabilitation. American Journal of 


3. Campagnolo DI. Book Review: Handbook of Physical Medicine and Rehabilitation Basics. 

American Journal of Rehabilitation. 1996;75(3):231. 

4. Campagnolo DI, Cheu JW. Central nervous system anatomy. PM&R State of the Art Review. 

1996;10(3):367-386. 

5. Campagnolo DI. Guest Editor: Rehab in Review. 1999;7(8). 

6. Campagnolo DI. Invited Commentary on Anderson AJ. Mechanisms and pathways of 

inflammatory responses in CNS trauma: spinal cord injury. J Spinal Cord Med. 2002; 25:178. 

REPORTS 

1. Simultaneous Bilateral Patellar Tendon Rupture: A Case Report and Literature Review. Oral 

presentation at: The First Annual Resident’s Research Day. June 20, 1990. Newark, New 

Jersey. 

2. Joint Injection and Aspiration. Grand Rounds; Department of Physical Medicine and 

Rehabilitation. UMDNJ-New Jersey Medical School. March 1, 1991. Newark, New Jersey. 

Revised 6/9/2008


Page 21 of 22 

3. Neck and Back: Biomechanics Didactic Lecture Series. Department of Physical Medicine 

and Rehabilitation. UMDNJ-New Jersey Medical School. 1990, 1991, & 1992. Newark, New 

Jersey. 

4. Antipsychotic Medications. Traumatic Brain Injury Lecture Series. Kessler Institute for 

Rehabilitation. June 14, 1991. East Orange, New Jersey. 

5. Resident Research Education. AAPM&R Resident Physician Council. Newsletter. June 

1992. 

6. Complications of Traumatic Brain Injury. Orientation Lecture Series. Department of Physical 

Medicine and Rehabilitation. UMDNJ-New Jersey Medical School. August 1992 and 1993. 

Newark, New Jersey. 

7. Motor Systems. Resident Didactic Series. Department of Physical Medicine and 

Rehabilitation. UMDNJ-New Jersey Medical School. September 23, 1992. Newark, New 

Jersey. 

8. Neuropharmacology in Traumatic Brain Injury. Resident Didactic Series. September 1993. 

9. Respiratory Dysfunction: Assessment and Management at Acute Care Management of the 

Spinal Cord Injured Person. Kessler Institute for Rehabilitation. October 15, 1993. 

10. Medical Complications of Spinal Cord Injury. Annual Review Course in Physical Medicine 

and Rehabilitation. UMDNJ-New Jersey Medical School and Kessler Institute for 

Rehabilitation. 1994-present. Ramada Hotel. East Hanover, New Jersey. 

11. Urodynamics Workshop: Voiding Dysfunction Following Brain Injury. Academy of Physical 

Medicine and Rehabilitation Annual Meeting. 1993. 

12. Spinal and Peripheral Control of Immune Function: Basic Mechanisms and Clinical 

Manifestations. Presented at the Winter Conference on Brain Research. January 1995. 

13. Effect of Timing of Stabilization on Length of Stay and Medical Complications Following 

Spinal Cord Injury. Presented at the 12th Annual North American Spine Society Meeting. 

October 22-25, 1997. 

14. Sanchez W, Campagnolo DI. Computer-Based Training of Spinal Cord Injury for Health 

Care Professionals. Presented at the Eighth Annual Ottawa Conference on Medical 

Education and Assessment. July 12-15, 1998. Philadelphia, Pennsylvania. 

15. Campagnolo DI, Bartlett JA, Keller SE. A Review of Level of Injury-Related Immune 

Alteration Following SCI. American Paraplegia Society. September 7, 1999. Las Vegas, 

Nevada. 

Revised 6/9/2008


Page 22 of 22 

16. Foye PM, Stitik TP, Campagnolo DI, Nadler SF, Chen B. Results of Cadaver-Based 

Anatomy Teaching for PM&R Residents. Poster Presentation. Association of Academic 

Physiatrists 36th Annual Educational Conference. March 1-4, 2000. San Diego, California. 

17. Campagnolo DI. Lateral Cutaneous Nerve of the Calf: A Nerve Conduction Technique. 

American Association of Electrodiagnostic Medicine. 47th Annual Scientific Meeting. 

September 13-16, 2000. Philadelphia, Pennsylvania. 

18. Campagnolo DI. Enhancing Resident Physician Training with Personal Digital Assistants 

(PDAs). Presented at UMDNJ Master Educators’ Guild and The Integrated Advanced 

Information Management Systems (IAIMs) Project. Robert Wood Johnson Medical School. 

May 3, 2002. Piscataway, New Jersey. 

19. Vizcarra G, Dixon D, Campagnolo DI, Bartlett JA, Keller SE. Stress, Depression, and TNF 

in Spinal Cord Injury. Presented at the 10th Annual PsychoNeuroImmunology Research 

Society. June 4-8, 2003. Amelia Island, Florida. 

20. Campagnolo DI, Padilla N. Spinal Cord Injury: Computer-Based Distance Learning. 

Presented at the NJEdge.Net Annual Conference. Technology in Education. October 30, 

2003. Plainsboro, New Jersey. 

Revised 6/9/2008

JOHN R - Center for Adaptive Neural Systems - Arizona State ...

Create successful ePaper yourself

Delete template?

Save as template?